PMID: 7539400Feb 1, 1995Paper

A new monoclonal antibody (A78-G/A7) to the Thomsen-Friedenreich pan-tumor antigen

Hybridoma
U KarstenF G Hanisch

Abstract

A new monoclonal antibody to the Thomsen-Friedenreich (TF) antigen (or, more precisely, epitope; Gal beta 1-3GalNAc-) has been developed that is specific for both anomeric forms of this disaccharide (TF alpha and TF beta, including related structures on glycolipids), and not assay restricted. We demonstrate that this avid antibody (A78-G/A7) is well suited for immunohistochemistry on paraffin-embedded and cryosectioned tissues, immunoblotting, ELISA techniques, and hemagglutination. Immunohistochemistry on paraffin sections does not require proteolytic or microwave pretreatment. The binding characteristics of this antibody are largely independent of variations in pH (6.0-8.2) and temperature (4-37 degrees C). Immunoblotting with KG-1 (human acute myelogenous leukemia) cells revealed a series of TF-active glycoproteins with a main band at about 155 kDa. Immunoprecipitation was performed using a new technique applicable to IgM-type antibodies.

References

Apr 8, 1985·Journal of Immunological Methods·M P WoodwardR A Bloodgood
Aug 15, 1989·Cancer·N BarrG F Springer
Jun 26, 1987·Journal of Immunological Methods·W D Matthew, A W Sandrock
May 1, 1973·International Journal of Cancer. Journal International Du Cancer·J BubeníkJ Donner
Nov 1, 1973·Journal of the National Cancer Institute·H D SouleM Brennan
Nov 1, 1973·Journal of the National Cancer Institute·D J GiardW P Parks
Sep 1, 1974·Journal of the National Cancer Institute·R CailleauW J Reeves
Jun 15, 1984·Science·G F Springer
Feb 1, 1954·The Journal of Experimental Medicine·R DULBECCO, M VOGT

❮ Previous
Next ❯

Citations

Feb 18, 2006·Cancer Immunology, Immunotherapy : CII·Antje DanielczykSteffen Goletz
Aug 29, 2013·Analytical Chemistry·Nan LiKagan Kerman
Jul 22, 2005·Immunology and Cell Biology·Fernando J IrazoquiGustavo A Nores
Mar 20, 2010·Journal of Reproductive Immunology·U JeschkeA Makrigiannakis
Dec 14, 1999·The Journal of Investigative Dermatology·C C ZouboulisC E Orfanos
Apr 10, 2008·International Journal of Cancer. Journal International Du Cancer·Yi CaoReinhard Schwartz-Albiez
Nov 14, 1997·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·Y CaoU Karsten
Jul 28, 2013·SpringerPlus·Uwe Karsten, Steffen Goletz
Nov 14, 2002·Laboratory Investigation; a Journal of Technical Methods and Pathology·Yi CaoReinhard Schwartz-Albiez
May 14, 2003·Histochemistry and Cell Biology·Udo JeschkeRenate Stahn
Apr 4, 2003·The Journal of Biological Chemistry·Arne EngelsbergArmin Rehm
Oct 23, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sonia SchoonbroodtRené M Hoet
Feb 6, 2002·Journal of Molecular Biology·Steffen GoletzUwe Karsten
Oct 11, 2011·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Senthil R KumarSusan L Deutscher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.